ESTRO 2024 - Abstract Book

S5805

RTT - Education, training, advanced practice and role developments

ESTRO 2024

The pilot was undertaken within a Radiotherapy Centre in North West England. RTTs developed a questionnaire containing validated PROMs tools (IIEF-5, IPSS and ALERT-B) to provide quantitative measures of toxicity. Lifestyle questions (adapted from a previous clinical audit) included alcohol/caffeine intake, smoking status and BMI. RTTs contacted patients who received prostate HDR-brachytherapy (as salvage treatment, monotherapy or boost + EBRT) 6-36 months prior (n=45). Participation and consent were obtained by telephone; questionnaires were sent by post.

The small sample size of eligible participants did not support use of inferential statistics, therefore descriptive statistics were used.

Clinical audit approval was acquired.

Results:

28 (62%) patients returned questionnaires; demographic data is shown in table 1.

Table 1. Patient Demographic Data

Mean age (years):

67.8 (50-78)

T Stage

T2a-T2c

7

T3a

8

T3b

12

T4a

1

Gleason

Grade Group 1

1

Grade Group 2

4

Grade Group 3

2

Grade Group 4&5

18

N/A

3

Hormone Status:

6 months

5

2-3 years

18

N/A

5

Dose/Modality:

15Gy Brachytherapy+EBRT(37.5Gy/15#)

20

27Gy/2# Salvage

4

27Gy/2# or 19Gy/1# Monotherapy

4